This is not our API. This repository is an independent, third-party profile of a company's publicly available API surface, maintained by API Evangelist. API Evangelist does not operate, host, resell, or support this company's APIs, and is not affiliated with or endorsed by the company unless stated on the profile.
Where the information came from. Everything here is assembled from material a member of the public can reach with a browser and no credentials — the company's own website, developer portal and documentation, the specifications it publishes for public use (OpenAPI, AsyncAPI, JSON Schema,
apis.json,llms.txtand similar), its public repositories, and its public status, pricing and changelog pages. Nothing here is obtained by breaching a system, defeating an access control, or using credentials of any kind.The rating is an independent assessment. The Kin Score and Agent Readiness rating are independently calculated scores of a company's public API artifacts, produced by API Evangelist against a published rubric. They are not certifications, endorsements, security assessments, or audits, and they score published artifacts — not the quality, safety, or security of the software.
Corrections, re-scores, and removal are free. No partnership, contract, or purchase is required, and you do not need to justify the request.
- Something wrong? Open an issue on this repository, or email info@apievangelist.com.
- Published something new? Ask for a re-score and we will re-run the rating.
- Want the listing taken down? Say so and we will honor it. The profile is reduced to your company name, a factual description, and a link to your own site, and the company is recorded as unrated — never scored zero for having asked.
Response times. Acknowledgement within one business day; removal or restriction within two business days; corrections and re-scores within five business days.
On a security or compliance team? Email info@apievangelist.com with security in the subject line and you will get a person, not a form. We will tell you exactly which public URLs this profile was built from so your team can see the same surface we did, and we will take the listing down on request while you work through it.
Full detail: Where this data comes from
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. As a pioneer in biotechnology since 1980, Amgen uses living cells to make biologic medicines addressing cardiovascular metabolic conditions, oncology, inflammation, rare diseases, and bone health, operating in approximately 100 countries worldwide.
Run: Capabilities Using Naftiko
- Biotechnology, Biopharmaceutical, Oncology, Inflammation, Cardiovascular, Rare Disease, Biosimilars, Life Sciences
- Created: 2024-01-01
- Modified: 2026-04-19
Amgen discovers, develops, manufactures, and delivers innovative biologic medicines for patients with serious illnesses. The company does not currently publish a public developer API.
Human URL: https://www.amgen.com
- Biotechnology, Biopharmaceutical, Life Sciences
| Name | Description |
|---|---|
| Biologic Drug Discovery | Pioneering use of living cells and human genetic data combined with AI and generative biology to discover novel biologic medicines. |
| Oncology Therapeutics | Cancer medicines targeting solid tumors and hematologic malignancies including innovative BiTE and antibody therapies. |
| Cardiovascular and Metabolic Medicines | Medicines addressing heart disease, high cholesterol (Lp(a)), obesity, and obesity-related metabolic conditions. |
| Inflammation Therapeutics | Treatments for inflammatory conditions including chronic rhinosinusitis with nasal polyps, asthma, and other immune-mediated diseases. |
| Rare Disease Medicines | Therapies for rare conditions including IgG4-related disease (IgG4-RD), generalized myasthenia gravis, and other orphan indications. |
| Bone Health Products | Medicines for osteoporosis, bone metastases, and other bone health conditions including PROLIA and XGEVA. |
| Biosimilars | High-quality biosimilar medicines providing more affordable alternatives to reference biologic therapies across multiple therapeutic areas. |
| AI-Driven Drug Development | Application of artificial intelligence, generative biology, and advanced data science to accelerate drug discovery and clinical trial optimization. |
| Name | Description |
|---|---|
| Cancer Treatment | Providing oncology medicines for patients with solid tumors and blood cancers through innovative biologic and targeted therapies. |
| Heart Disease Prevention | Reducing cardiovascular risk with medicines targeting LDL cholesterol, Lp(a), and other cardiovascular risk factors. |
| Inflammatory Disease Management | Managing chronic inflammatory conditions with targeted biologic therapies for patients with severe unmet medical needs. |
| Rare Disease Treatment | Delivering life-changing therapies to patients with rare and ultra-rare diseases where few or no other treatments exist. |
| Biosimilar Access | Improving patient access to biologic therapies through high-quality, lower-cost biosimilar medicines. |
| Weight Management | Addressing obesity and obesity-related conditions with novel medicines targeting metabolic pathways. |
| Name | Description |
|---|---|
| Amgen SupportPlus | Patient support program providing financial assistance, insurance navigation, and access services for Amgen medicines. |
| Clinical Trials Network | Global clinical research network conducting Phase I through Phase III trials across therapeutic areas with AI-optimized trial design. |
| Amgen Biosimilars | Portfolio of biosimilar medicines offered through partnerships with healthcare systems globally to improve treatment access. |
FN: API Evangelist
Email: info@apievangelist.com